Introduction {#s01}
============

Skeletal muscle accounts for 38--54% and 28--39% of total body mass in healthy men and women, respectively. These ranges are dependent on multiple factors, including age, physical activity level, nutritional input, overall health, and genetic makeup. Skeletal muscle comprises a heterogeneous mix of specialized myofibers that differ in their physiologic, metabolic, and biochemical attributes. On the ends of that spectrum are the slow, oxidative fibers of endurance athletes, comprising type I myosin heavy chain (MHC) proteins, and the fast, glycolytic fibers of power and strength athletes, comprising types IIa and IIx, and in rodents, IIb, MHC proteins. Interestingly, several clinical studies have demonstrated that resistance training, resulting in the maintenance of, and/or hypertrophy of, fast, glycolytic fibers can improve the cardiometabolic disease risk profile of patients with type 2 diabetes mellitus ([@bib20]). Consistent with those findings, it is the fast, glycolytic fibers that atrophy at a greater rate than the slow, oxidative fibers during food deprivation, cancer-associated cachexia, glucocorticoid administration, and age-related sarcopenia ([@bib20]; [@bib3]).

At the molecular level, the PI3K/Akt/mTOR signaling pathway has emerged as a key regulator of glycolytic muscle growth and metabolism in response to growth factors, insulin, resistance exercise, and nutritional input. Transgenic overexpression of Akt in skeletal muscle selectively promotes muscle hypertrophy ([@bib19]), and its expression in glycolytic muscles promotes weight loss and insulin sensitivity in obese mice ([@bib14]) and in aged mice that display a state of anabolic resistance and impaired activation of Akt ([@bib1]). Functional overload ([@bib2]) and IGF-1 stimulation ([@bib30]; [@bib34]) positively regulate PI3K/Akt/mTOR signaling in muscle and promote hypertrophy. Conversely, myostatin acts as a negative regulator of muscle hypertrophy, in part, through activation of an "atrogene" program ([@bib5]), and in part, by inhibiting PI3K/Akt/mTOR signaling ([@bib31]; [@bib7]). These molecular pathways converge on transcriptional programs that coordinate the cellular anabolic and catabolic processes mediated by changes in Smad signaling.

Advances in whole transcriptome sequencing have shown that \>70% of the genome is actively transcribed ([@bib21]) and that ∼2 of every 3 transcripts do not encode for a protein ([@bib13]). Long noncoding RNAs (lncRNAs) are a class of genes, with little to no coding potential ([@bib11]), which are known to recruit chromatin-modifying complexes to genomic loci to regulate gene expression ([@bib17]; [@bib10]). Prior studies in cell culture have indicated that the lncRNAs MUNC ([@bib23]; [@bib24]) and LncMyoD ([@bib6]) promote myoblast differentiation and fusion in vitro by stimulating the transcription of MyoD, MyoG, and Myh3 and by negatively regulating the translation of Nras and Myc, respectively. However, the biological roles of lncRNAs in conditions of age-associated muscle atrophy have not, to our knowledge, been explored. Here, we describe a muscle-enriched lncRNA, called Chronos, which is negatively regulated by Akt signaling and positively regulated with advancing age. Chronos is shown to repress hypertrophic growth in vitro and in vivo, in part, by negatively regulating Bmp7 expression.

Results and discussion {#s02}
======================

Inducible overexpression of constitutively active Akt1 in type IIb glycolytic myofibers has been previously demonstrated to induce muscle hypertrophy and promote strength ([@bib14]). RNAseq data obtained from that mouse model ([@bib38]) was mined for lncRNAs, yielding numerous (∼352) putative lncRNAs whose expression was significantly changed by the activation of the Akt1 transgene ([Fig. 1 A](#fig1){ref-type="fig"}). The lncRNA Gm17281, now referred to as Chronos, is significantly repressed in the hypertrophic muscle of TRE-myrAkt1/MCK-rtTA mice ([Fig. 1, B and C](#fig1){ref-type="fig"}). Northern blot analysis revealed marked enrichment of the ∼3.6-kb Chronos transcript in skeletal muscle and heart, compared with other tissues ([Fig. 1 D](#fig1){ref-type="fig"}), and quantitative PCR analysis indicated Chronos is enriched in muscles with a greater percentages of type IIb glycolytic myofibers ([Fig. 1 E](#fig1){ref-type="fig"}), thus suggesting a biological role in striated muscle. To uncover the biological role of Chronos, its expression was examined in models of muscle regeneration and acute atrophy. Chronos expression is significantly decreased 14 d after cardiotoxin (CTX) injury of muscle ([Fig. 1 F](#fig1){ref-type="fig"}), a model that is associated with robust activation of Akt signaling ([@bib39]). Chronos expression is unchanged in the hind limb--unloading and type 1--diabetic mouse models, despite significant losses of gastrocnemius muscle mass ([Fig. 1, G--J](#fig1){ref-type="fig"}). Aging leads to a progressive loss of muscle mass in mice ([@bib1]). Northern blot ([Fig. 1 K](#fig1){ref-type="fig"}) and quantitative PCR ([Fig. 1 L](#fig1){ref-type="fig"}) analysis revealed a progressive increase in Chronos expression with advancing age. Together, these data indicate that Chronos is an aging-related, Akt-inhibited lncRNA, whose expression is uncoupled from acute muscle loss.

![**Chronos is a growth-associated and muscle-enriched lncRNA.** (A) Heat map depicting differentially expressed lncRNAs from doxycycline-treated TRE-myrAkt1/MCK-rtTA and MCK-rtTA (control) mice. (B) RNAseq read profile of Chronos. Data are plotted on a log~2~ scale. (C) Chronos expression (FPKM). \*, P \< 0.05 from *n* = 4 TRE-myrAkt1/MCK-rtTA and *n* = 4 MCK-rtTA mice. (D) Tissue distribution of Chronos in 2-mo-old mice. (E--J) Data are means ± SD. (E) Chronos expression in the muscles of *n* = 3 2-mo-old mice. (F) Chronos expression 14 d after CTX injury. \*, P \< 0.05 from *n* = 8 independent experiments. (G and H) Hind limb unloading--induced muscle atrophy. \*, P \< 0.05 from *n* = 6 control and *n* = 5 unloaded mice. (G) Normalized muscle wet weight. (H) Quantitative PCR analysis of Chronos expression. (I and J) Type 1 diabetes model of muscle atrophy. \*, P \< 0.05 from *n* = 6 saline and *n* = 6 STZ-injected mice. (I) Normalized muscle wet weight. (J) Quantitative PCR analysis of Chronos expression. (K) Chronos expression in muscle from 2--24-mo-old mice. (L) Quantitative PCR analysis of Chronos expression in gastrocnemius muscle. \*, P \< 0.05 from *n* = 4 young and *n* = 4 aged mice. Data are means ± SD.](JCB_201612100_Fig1){#fig1}

To explore the biological role of Chronos, loss-of-function experiments were performed in myoblasts. Cells treated with Chronos siRNAs (siChronos), as compared with negative-control siRNAs (siNC1), display thicker and more highly branched MHC^+^ myotubes by d 3, with clearly visible hypertrophy by d 3 and 5 ([Fig. 2 A](#fig2){ref-type="fig"}). To examine the biological role of Chronos in vivo, siNC1 was injected into either the left or right tibialis anterior (TA) muscle with the contralateral TA injected with either siChronos or siMyostatin. Immunofluorescence labeling of laminin and quantification of TA myofiber cross sections indicated siChronos treatment resulted in myofiber hypertrophy, as indicated by the flattening and rightward shift of the myofiber size-distribution curve ([Fig. 2, B and C](#fig2){ref-type="fig"}). In total, that treatment resulted in a significant, 42% increase in the mean myofiber cross-sectional area in the siChronos-treated mice ([Fig. 2 D](#fig2){ref-type="fig"}). Importantly, the biological effect of siChronos paralleled the effects of siMyostatin, which was used as a positive control ([@bib18]; [@bib16]). Together, these data demonstrate that inhibition of Chronos expression results in hypertrophic growth both in vitro and in vivo.

![**Inhibition of Chronos results in hypertrophic growth.** (A) Immunostaining of myoblasts during in vitro differentiation. Bars, 100 µm. (B--D) Inhibition of Chronos in vivo. Data were acquired 14 d after siRNA injection. (B) Immunostaining of TA anterior cross sections. Bars, 50 µm. (C) Myofiber size distribution. (D) Mean myofiber cross-sectional area. Data are means ± SEM. \*, P \< 0.05 relative to siNC1.](JCB_201612100_Fig2){#fig2}

To test the hypothesis that Chronos negatively regulates hypertrophic growth-factor signaling, the in vivo siRNA injections were repeated and assayed for changes in gene expression at the 7-d time point. Transcripts examined included members of the TGF-β family; receptors for, and extracellular modulators of, those ligands; and other genes known to be involved in muscle growth processes ([@bib22]). Of the 28 genes examined, only *Bmp7*, *Fst*, *Acvr1b*, and *Gdf6* transcripts were significantly different among groups ([Fig. 3 A](#fig3){ref-type="fig"} and Fig. S1), with *Bmp7* displaying the most robust change in expression. During in vitro myogenesis, Chronos expression decreased on d 1--3, with its expression increasing to levels greater than that observed in proliferating myoblasts by d 5 ([Fig. 3 B](#fig3){ref-type="fig"}). Similar to in vivo observations, *Bmp7* transcript levels were robustly increased in differentiating myoblasts treated with siChronos as compared with siNC1 ([Fig. 3 C](#fig3){ref-type="fig"}). In addition, treatment with siChronos results in a nearly twofold increase in the induction of Mef2a ([Fig. 3 D](#fig3){ref-type="fig"}) and a subtle, but significant, increase in MyoG expression ([Fig. 3 E](#fig3){ref-type="fig"}) suggesting that Chronos has a role in regulating myogenesis in vitro.

![**Inhibition of Chronos activates hypertrophic signaling.** (A--N) Mean values are represented by white (siNC1) or red (siChronos) boxes or circles. Data are means ± SD. \*, P \< 0.05. (A) Analysis of gene expression from *n* = 6 independent experiments. Samples were acquired 7 d after siRNA injection. (B--E) Data are presented normalized to gene expression at d 0 from *n* = 4 independent experiments. (F) Quantification of secreted Bmp7 after 3 d differentiation. \*, P \< 0.05 from *n* = 8 independent experiments. (G) Representative Western blots of the cells from F. (H and I) Quantification of the relative changes in Smad1/5 (H) and Smad2 (I) phosphorylation. (J) Representative Western blot of puromycin incorporation in differentiating myoblasts. (K) Quantification of J. (L) Immunoprecipitation of ubiquitinylated myosin. (M) Representative Western blot of puromycin incorporation in mature myotubes. (N) Quantification of M. (J-K, M-N) Data are from *n* = 3 independent experiments.](JCB_201612100_Fig3){#fig3}

Bmp signaling in general ([@bib32]), and the Bmp7 ligand specifically ([@bib36]), has been shown to positively regulate skeletal muscle hypertrophy through activation of Smad1/5. To corroborate the observed changes in *Bmp7* transcript levels, secreted Bmp7 protein was quantified in differentiating myoblasts. Myoblasts treated with siChronos were found to secrete significantly more Bmp7 protein as compared with controls ([Fig. 3 F](#fig3){ref-type="fig"}). Cell lysates from these cultures were assayed for the activating phosphorylation of the Smad1/5 and Smad2 signaling pathways. Consistent with a prior report ([@bib4]), myoblast differentiation is associated with a steady decrease in pro-hypertrophic Smad1/5 phosphorylation ([Fig. 3, G and H](#fig3){ref-type="fig"}). Treatment with siChronos led to a robust and significant enhancement of Smad1/5 phosphorylation at days 3 and 4 of differentiation ([Fig. 3, G and H](#fig3){ref-type="fig"}). Further, inhibition of Chronos resulted in a consistent repression of anti-hypertrophic Smad2 phosphorylation at all time points ([Fig. 3, G and I](#fig3){ref-type="fig"}).

To further corroborate these observations, changes in protein synthesis and degradation were assayed on d 3--5 of differentiation. Differentiating myoblasts treated with siChronos displayed significant increases in puromycin incorporation, indicative of increased protein synthesis, as compared with siNC1 on d 3 and 4 of differentiation ([Fig. 3, J--K](#fig3){ref-type="fig"}). Next, ubiquitinylated myosin was quantified in C2C12 cells on d 3--5 of differentiation as a measure of protein degradation. A decrease in ubiquitinylated (coimmunoprecipitated) myosin was consistently observed in cells treated with siChronos as compared with siNC1 on d 4 and 5 ([Fig. 3 L](#fig3){ref-type="fig"}). Although a faint myosin signal was observed to be coimmunoprecipitated with ubiquitin on d 3 with siNC1 treatment, that was not quantified as the input signal was less than the detection threshold. Additionally, the effects of siChronos on protein synthesis in myotube cultures were examined. Myoblasts on d 4 of differentiation were treated with siChronos or siNC1 and assayed for puromycin incorporation. In that model, significant increases in protein synthesis were observed 48 and 72 h after treatment with siChronos ([Fig. 3, M and N](#fig3){ref-type="fig"}). Together, these results indicate that inhibition of Chronos biases the anabolic/catabolic signaling axis toward anabolic processes, perhaps through increased Bmp7 signaling, in both developing and more-mature myotubes.

To extend those in vitro observations, the role of *Bmp7* in siChronos-mediated hypertrophy was tested in vivo. Transverse sections of TA muscles treated with siChronos, siChronos and siBmp7, and siNC1 were analyzed by immunofluorescence staining of laminin ([Fig. 4 A](#fig4){ref-type="fig"}). In agreement with earlier experiments ([Fig. 2 C](#fig2){ref-type="fig"}), siChronos treatment resulted in a flattening and a rightward shift of the myofiber size-distribution curve ([Fig. 4 B](#fig4){ref-type="fig"}) and an increase in the mean myofiber cross-sectional area ([Fig. 4 C](#fig4){ref-type="fig"}). Co-injection of siBMP7 with siChronos resulted in significantly less hypertrophic growth as compared with siChronos treatment alone ([Fig. 4 C](#fig4){ref-type="fig"}). Collectively, these in vitro and in vivo observations are consistent with the notion that *Bmp7* functionally participates in the control of myofiber hypertrophy downstream of Chronos.

![**Chronos inhibits hypertrophy through repression of Bmp7 in vivo.** (A) Immunostaining of TA cross sections. Bars, 50 µm. (B) Myofiber size distribution. (C) Mean myofiber cross-sectional area. Data were acquired 14 d after siRNA injection. Data are means ± SEM. \*, P \< 0.05 relative to siNC1; ^†^, P \< 0.05 relative to siChronos.](JCB_201612100_Fig4){#fig4}

lncRNAs are known to recruit chromatin modifiers to genomic sequences, thereby regulating the epigenetic landscape and gene expression ([@bib9]; [@bib12]; [@bib27]; [@bib28]). To assess the possibility that Chronos functions through a similar mechanism, we first performed an in silico alignment of Chronos with the Bmp7 promoter (−10,000 nt) relative to the transcriptional start site (TSS). This analysis identified two sequences within Chronos, each with a high degree of sequence similarity to four regions of the Bmp7 promoter. A de novo motif search of the promoter region yielded an ∼100-nt motif contained within each of the four homology regions identified in the in silico alignment. Together, those analyses identified two sequences of Chronos with antisense complementarity (77--85% similarity) to four genomic regions (denoted -7655, -7310, -6276, and -5494) that each contain the de novo identified motif (Fig. S2). To investigate the functional significance of those motifs, a 2.7-kb region encompassing the four genomic regions (-7950 to -5242), as well as two putative promoter sequences (-3674 to +3, and -1571 to +3) were subcloned into a promoter-less luciferase vector ([Fig. 5 A](#fig5){ref-type="fig"}). Luciferase activities were induced ∼7--12-fold with the short and long Bmp7 promoter sequences ([Fig. 5 B](#fig5){ref-type="fig"}), thus indicating promoter activity in the context of myoblast differentiation. Addition of siChronos had no effect on luciferase activity directed by either of those promoter sequences. However, addition of the 2.7-kb region containing the Chronos homology motifs led to a reduction in luciferase activity from both Bmp7 promoter constructs on d 1 of differentiation. Notably, addition of siChronos completely abrogated the repressive effects of the 2.7-kb Chronos homology region ([Fig. 5 B](#fig5){ref-type="fig"}). For further validation, the 2.7-kb region was inserted into a luciferase expression vector upstream of the heterologous SV40 promoter. When analyzed in proliferating myoblasts, the presence of the 2.7-kb region was sufficient to repress luciferase activity ([Fig. 5 C](#fig5){ref-type="fig"}). Luciferase activity was restored to ∼50% of control after 24 h of differentiation, and the addition of siChronos completely abrogated the inhibitory effects of the Chronos homology region. Together, these data indicate that the Chronos homology region upstream of Bmp7 functions as a Chronos-responsive transcriptional repressive element.

![**Chronos regulates Bmp7 transcription via and upstream repressor.** (A--C) Chronos response region (purple). Bmp7 promoters of -1571 to +3 (orange) and -3674 to +3 (green). (A) Schematic of Bmp7 locus. (B and C) Luciferase reporter assay in proliferating myoblasts (d 0) and after 24 h of differentiation (d 1) ± siChronos. Data are means ± SD from *n* = 8 independent experiments. \*, P \< 0.05 relative to d 0. (B) Luciferase activities driven by genomic sequences from A. (C) Luciferase activity in response to Chronos response region immediately upstream of the SV40 promoter. (D) RNA Pol II occupancy of Bmp7 TSS. (E) Ezh2 occupancy of genomic regions -7885 and -3389 relative to Bmp7. (D and E) Data are means ± SD from *n* = 3 independent experiments. \*, P \< 0.05 relative to d 0. (F--I) Quantification of changes in gene expression. Data are presented normalized to gene expression at d 0 from *n* = 3 independent experiments. Data are means ± SD. \*, P \< 0.05. (J) Immunostaining of myoblasts during differentiation. The red box indicates the location of the high magnification image to the right. Bars, 100 µm.](JCB_201612100_Fig5){#fig5}

To extend those observations, we performed Pol II chromatin immunoprecipitation (ChIP) on nuclear extracts from proliferating and differentiating myoblasts. The RNA Pol II occupancy of the Bmp7 TSS was observed to increase ∼11.7-fold (4.9 ± 1.7 to 57.7 ± 6.6 binding events per 1000 cells) in myoblasts on d 2 of differentiation in the presence of siChronos as compared with d-0 controls ([Fig. 5 D](#fig5){ref-type="fig"}). Those observations, consistent with the increase in Bmp7 expression after siChronos treatment in vitro ([Fig. 3 C](#fig3){ref-type="fig"}) and in vivo ([Fig. 3 A](#fig3){ref-type="fig"}), suggest that Chronos recruits an epigenetic modifier or transcriptional corepressor to the *Bmp7* locus. To explore that possibility, a combination of RNA pull-down assays and candidate screens for RNA binding proteins was used (Fig. S3). Of the putative RNA binding proteins, *Ezh2* was selected for subsequent analyses because it is known to be recruited to genomic loci by lncRNAs ([@bib29]; [@bib9]). Ezh2 ChIP analysis revealed a 68% decrease in Ezh2 occupancy of the -7885 site in differentiating myoblasts in the presence of siChronos as compared with the control ([Fig. 5 E](#fig5){ref-type="fig"}). No change in Ezh2 occupancy was observed at the -3389 site, thus indicating specificity. Although these luciferase reporter and ChIP data indicate that Chronos' repressive effects on *Bmp7* transcription are dependent on the Chronos homology region, and mediated by *Ezh2*, further studies will be required to test whether the formation of a lncRNA:DNA heteroduplex is involved in the regulation of the *Bmp7* locus.

Experiments also tested whether Chronos overexpression was sufficient to inhibit myotube maturation and hypertrophy. Myoblasts transfected with Chronos 98--3259 or Chronos 1467--3259 displayed significantly impaired *Bmp7* induction as compared with empty vector controls ([Fig. 5 F](#fig5){ref-type="fig"}). Ectopic expression of Chronos 98--3259 or Chronos 1467--3259 similarly impaired and/or delayed the induction of *MyoG*, *Myh1*, and *Myh2* ([Fig. 5, G--I](#fig5){ref-type="fig"}). Finally, myoblasts transfected with Chronos 98--3259 or 1467--3259 exhibited impaired myogenesis as indicated by spindly MF20-positive cells with a paucity of nuclei as compared with empty vector control ([Fig. 5 J](#fig5){ref-type="fig"}). Importantly, myoblasts overexpressing Chronos phenocopy myoblasts treated with siBmp7 ([Fig. 5 J](#fig5){ref-type="fig"}).

Our findings identify Chronos as a muscle-enriched, Akt-inhibited, aging-related lncRNA that functions as an inhibitor of hypertrophic growth. Chronos, however, does not appear to function as a classical "atrogene" because its expression is uncoupled from the loss of muscle mass in models of acute atrophy. Physiologic maintenance of muscle mass is dependent on the proper balance of multiple signaling pathways, including (a) the TGF-β family, activins, and GDFs, including myostatin, which both inhibit Akt1 and lead to the activation of an atrogene program via activation of Smad2/3 ([@bib7]; [@bib5]); and (b) BMPs and GDFs, which activate Akt1 to inhibit activation of an atrogene program through activation of Smad1/5/8 ([@bib32]; [@bib7]). Our data indicate that Chronos functions to alter that balance, in part, through repression of Bmp7, and are consistent with prior studies documenting the hypertrophic effects of Bmp signaling in general ([@bib32]), and the Bmp7 ligand specifically ([@bib36]). Although our data suggest a direct effect of Chronos on Bmp7 transcription, we cannot rule out the inhibitory effects of an unknown peptide encoded by Chronos. Future studies to identify potential Chronos-encoded micropeptides, additional Chronos-targeted loci, and its human homologue are of great interest.

Materials and methods {#s03}
=====================

Mouse models {#s04}
------------

Inducible Akt1 transgenic mice have been previously described ([@bib14]; [@bib38]). In brief, constitutively active Akt1 transgenic mice (TRE-myrAkt1) were crossed with 1256\[3Emut\]MCK--reverse tetracycline transactivator (rtTA) transgenic mice. The 1256\[3Emut\]MCK promoter specifically expresses rtTA in type IIb glycolytic fibers. Transgene expression was activated by adding doxycycline (0.5 mg/ml) to the water.

Aged C57BL/6 mice were purchased from Charles River. Adult C57BL/6J were purchased from The Jackson Laboratory at 8--10 wk old and subjected to CTX injury, as previously described ([@bib26]) or injection of siRNA into the TA muscle, as previously described ([@bib18]). In brief, 40 µl of 10 µM CTX from *Naja mossambica mossambica* was injected into the TA muscle, whereas the contralateral TA muscle was injected with an equal volume of sterile saline. siRNAs were mixed with AteloCollagen (Koken Co.) at a final concentration of 10 µM, according to the manufacturer's instructions. After anesthetizing, 30 µl of the siRNA--AteloCollagen complex was injected into the TA muscle. The TA muscles were harvested and processed for analysis at 7 and 14 d after injection.

Hind limb unloading was performed on five 6-wk-old, female C57BL/6J mice for 7 d, as previously described ([@bib37]). In brief, the adhesive surface of a folded strip of adhesive foam (AliMed) was loosely applied longitudinally along the proximal two-third of the tail of the anesthetized mice. Elastoplast tape was wrapped circumferentially around the adhesive foam, and a wire was inserted in between the fold of the adhesive foam and then drawn up to a pulley attached to a 360° swivel hook at the top of the cage. The length of the wire was adjusted such that the toes of the hind limbs touched the cage floor only during full hind limb extension. Gastrocnemius muscles were collected from unloaded mice and their littermates as weight-bearing controls for RNA isolation. Gastrocnemius muscle wet weight (in milligrams) was normalized to total body weight (in grams).

Type 1 diabetes was induced in 9-wk-old C57BL/6J mice, purchased from The Jackson Laboratory, with daily i.p. injections of streptozotocin (STZ). In brief, mice received a daily i.p. injection of STZ (50 mg/kg body weight) or an equal volume of saline buffer for a consecutive 5 d. Fasting blood glucose levels were measured (Aviva Plus Accu-Chek blood glucose monitor) at 14-d after injection. STZ induced a significant increase in fasting blood glucose levels (387 ± 30.4 mg/ml, *n* = 6, P \< 0.001) as compared with that of nondiabetic control mice (111.7 ± 5.7 mg/ml, *n* = 6). Gastrocnemius muscles wet weight (in milligrams) was normalized to tibia length (in centimeters). All experiments were performed in adherence with National Institutes of Health guidelines on the use of laboratory animals and were approved by the Institutional Animal Care and Use Committee at Boston University.

RNAseq {#s05}
------

High-throughput RNA sequencing was performed on poly A+ RNA-derived cDNA of gastrocnemius muscles from double transgenic mice (1256\[3Emut\]MCK-rtTA × TRE-myrAkt1) and their MCK-rtTA littermates treated with 2 wk of doxycycline water ([@bib14]). RNAseq methodology, statistical analysis, and the data set have been previously described ([@bib38]). In brief, we used RSEM to identify transcripts in each sample and edgeR software (Bioconductor) for differential gene expression analysis. Transcripts expression altered ≥1.5-fold or −1.5-fold or less, P \< 0.05, and a false-discovery rate of \<0.05 were considered statistically different between the two groups. The UCSC Genome Database (University of California, Santa Cruz) was used as a reference to identify differentially expressed transcripts. Only those transcripts annotated as noncoding RNA were screened further.

Cell culture, siRNA {#s06}
-------------------

C2C12 cells were purchased from ATCC, and all experiments were performed with cells at a passage \<10. Cells were maintained in growth medium consisting of DMEM supplemented with 10% FBS (vol/vol). To induce differentiation, cells were grown to ∼70% confluency; at which point, the medium was changed to differentiation medium consisting of DMEM supplemented with 5% horse serum (vol/vol). In experiments involving differentiation with siRNAs, the siRNAs were added once the medium was changed to differentiation medium and every 48 h thereafter. Dicer substrate RNAs were purchased from Integrated DNA Technologies and transfected into cells with Lipofectamine RNAiMAX (Thermo Fisher Scientific) or injected into muscle with AteloCollagen. The siChronos was an equal mixture of three individual, custom siRNA duplexes that were designed online at <http://www.idtdna.com> (Integrated DNA Technologies). Sequences included siChronos (1-sense) 5′-RGRGRGRCRARCRCRARGRARGRARARGRARARARURGRCRARGRGGC-3′, siChronos (1-antisense) 5′-RGRCRCRCRURGRCRARURURURCRURURCRURCRURGRGRURGRCRCRCRURU-3′, siChronos (2-sense) 5′-RURCRCRCRCRGRCRURURCRARGRCRURGRURURURURCRURCRCTC-3′, siChronos (2-antisense) 5′-RGRARGRGRARGRARARARARCRARGRCRURGRARARGRCRGRGRGRGRARARA-3′, siChronos (3-sense) 5′-RGRARGRCRCRARCRGRARGRARCRCRCRURARURCRURGRARCRUGG-3′, and siChronos (3-antisense) 5′-RCRCRARGRURCRARGRARURARGRGRGRURCRURCRGRURGRGRCRURCRURG-3′.

Quantitative real-time PCR {#s07}
--------------------------

Total RNA was extracted with TRIzol (Invitrogen), and cDNA was reverse transcribed with M-MLV (Invitrogen). Quantitative real-time PCR was performed using the SYBR Select or Power SYBR Green Master Mixes (Applied Biosystems). The following primers were used for real-time PCR: Gm17281 qF1 5′‑TCTTCAACAGAGCCACGAGAC‑3′, Gm17281 qR1 5′‑TGTCCCCAAGTGTTACCAAGG‑3′, Gm17281 qF2 5′‑TCAGAGTTAGGAGAGTGGGGG‑3′, Gm17281 qR2 5′‑GTGGGTGTTCCCAGAAAATGC‑3′, Gm17281 qF3 5′‑GTCCTGGAGTCACAGTTCGC‑3′, Gm17281 qR3 5′‑GCATCTTGGGCTTAGGTGGA‑3′, Hprt qF1 5′‑GGTTAAGCAGTACAGCCCCA‑3′, Hprt qR1 5′‑TGCAGATTCAACTTGCGCTC‑3′, Tbp qF1 5′‑ACAGCCTTCCACCTTATGCTC‑3′, Tbp qR1 5′‑CTGTGCCGTAAGGCATCATTG‑3′, Bmp7 qF1 5′‑CTGTCCATCTTAGGGTTGCCC‑3′, Bmp7 qR1 5′‑GAACTCCCGATGGTGGTATCG‑3′, Bmp7 qF2 5′‑GGCTGGCAGGACTGGATCAT‑3′, Bmp7 qR2 5′‑GGCGCACAGCAGGGCTTGG‑3′, Gdf5 qF1 5′‑CCCCACGAATACATGCTCTCC‑3′, Gdf5 qR1 5′‑CCATCCTTCTCCAAGGCACTG‑3′, Gdf6 qF1 5′‑CGAACTCCACAAGAGAGTGCC‑3′, Gdf6 qR1 5′‑AGAGGAGTGTGCGAGAGATCG‑3′, Gdf11 qF1 5′‑GAAGAGGACGAGTACCACGC‑3′, Gdf11 qR1 5′‑GGCTGAAGTGGAAATGACAGC‑3′, Igf1 qF1 5′‑CTTCTGCTTGCTAAATCTCACTGTC‑3′, Igf1 qR1 5′‑GCCAGGTAGAAGAGGTGTGAAG‑3′, Inha qF1 5′‑GTCATCAGGGCAAGTGAACTATGG‑3′, Inha qR1 5′‑CAGCTGGCTGGTCCTCACAG‑3′, Inhba qF1 5′‑GGGTAAAGTGGGGGAGAACG‑3′, Inhba qR1 5′‑ACTTCTGCACGCTCCACTAC‑3′, Mstn qF1 5′‑CAGCAGTGATGGCTCTTTGG‑3′, Mstn qR1 5′‑CTTGCCATCCGCTTGCATTAG‑3′, Chrd qF1 5′‑CGACTGCTGCAAACAGTGTC‑3′, Chrd qR1 5′‑TGTGCAGTGGGAACAGCATC‑3′, Crim1 qF1 5′‑GGGGAGTGCTGTCCTTTACC‑3′, Crim1 qR1 5′‑GTTTCGTAGCTGTCCAGGGG‑3′, Kcp qF1 5′‑TCCTTGGTCCCTGGTGAGAC‑3′, Kcp qR1 5′‑CCTTCGGGACAGGTGTGAC‑3′, Fst qF1 5′‑GCTACTCTGCCAGTTCATGGAG‑3′, Fst qR1 5′‑CCGGTGCTGCAACACTCTTC‑3′, Twsg1 qF1 5′‑TAGCTCTAGCCTCCCTGACG‑3′, Twsg1 qR1 5′‑ACAGCATGCACTCCTTACAGC‑3′, Acvr1b qF1 5′‑GCTGCGCCATGAAAACATCC‑3′, Acvr1b qR1 5′‑GTCTGCAATGGCACACATGC‑3′, Acvr2b qF1 5′‑CATGAGGTGAGACAGTGCCAG‑3′, Acvr2b qR1 5′‑AGATTTCCCGTTCACTCTGCC‑3′, Igfr1 qF1 5′‑GCGAGCCTGGCATTTTACTG‑3′, Igfr1 qR1 5′‑TTGGAGCAGTAGTTGTGCCG‑3′, Slc2a4 qF1 5′‑ATCTTGATGACCGTGGCTCTG‑3′, Slc2a4 qR1 5′‑TGAGATCTGGTCAAACGTCCG‑3′, Foxo1 qF1 5′‑TCAAGGATAAGGGCGACAGC‑3′, Foxo1 qR1 5′‑CTCGCAGGCCACTTAGAAAAC‑3′, Fbxo32 qF1 5′‑GTGGCATCGCCCAAAAGAAC‑3′, Fbxo32 qR1 5′‑TGTAAGCACACAGGCAGGTC‑3′, Hdac4 qF1 5′‑TGTCTGCTCTGCTGGGAAAC‑3′, Hdac4 qR1 5′‑TGCGCCTCAATCAGAGAGTG‑3′, Cryab qF1 5′‑TGACCTCTTCTCAACAGCCAC‑3′, Cryab qR1 5′‑TCCCCCAGAACCTTGACTTTG‑3′, Psmc3 qF1 5′‑ATTGAGTTTCCAATGCCCAACG‑3′, Psmc3 qR1 5′‑GGACAGACTAGAGGTGTCCCC, Pacsin3 qF1 5′‑TTTCCGTAAAGCTCAGAAGCCC‑3′, Pacsin3 qR1 5′‑CATGTAGCGTGGGGTGTAGC‑3′, Atg13 qF1 5′‑GATTTGCACCCGCTCATCATC‑3′, Atg13 qR1 5′‑GCCTTCTTTGCTTCATGGGTG‑3′, Atp6ap2 qF1 5′‑TCTCCGAACTGCAAGTGCTAC‑3′, Atp6ap2 qR1 5′‑CACTGCGTTCCCACCATAGAG‑3′, Ambra1 qF1 5′‑TGCTTCTGGTTGCCTAGATGG‑3′, Ambra1 qR1 5′‑TGGAAAGCCAAGGAGGCTATG‑3′, Med14 qF1 5′‑TGGAATGTCACCAGCTAACCC‑3′, Med14 qF1 5′‑AGGAGCGCTGAGGTAGTTTTC‑3′, Mef2a qF1 5′‑TTTTTAAGACAATTTCAACGGCAGC‑3′, Mef2a qR1 5′‑ATCCGAGTTCGTCCTGCTTTC‑3′, Myog qF1 5′-TACAGGCCTTGCTCAGCTCC‑3′, Myog qR1 5′‑TGTGGGAGTTGCATTCACTGG‑3′, Myh1 qF1 5′‑ACGGTCGAAGTTGCATCCC‑3′, Myh1 qR1 5′‑TTCTGAGCCTCGATTCGCTC‑3′, Myh2 qF1 5′‑ATATAAAAGAGTCCCGAACGAGGC‑3′, Mhy2 qR1 5′‑TCTGGTCTTCTTTCACGGTCAG‑3′.

Luciferase reporter assay {#s08}
-------------------------

Genomic regions upstream of mouse *Bmp7* TSS were inserted upstream of Luc in either the pGL3-Basic Vector (Promega) or pISO (Addgene) containing the SV40 promoter/enhancer flanking Luc. Mouse Bmp7 promoter regions were amplified using forward (-3674) 5′-GCAGCTTCCAGACACAATGAC-3′, forward (-1571) 5′‑CCCTCAGACAGTCACATCACC-3′, and reverse (+3) 5′-CAAGGCTAGCACAGCAACTC-3′. Chronos recognition region was amplified using forward (-7950) 5′-TGAGAAAATCCCCATGTCCCC-3′ and reverse (‑5242) 5′‑ACTCTCCATGAAGGGCCAAAC-3′ and inserted upstream of Luc in both pGL3-Basic and pISO. C2C12 were transfected with equal amounts of plasmid DNA using Lipofectamine 2000 (Thermo Fisher Scientific). Renilla luciferase (pRL-TK) was used as a normalization control. The dual-luciferase reporter assay system (Promega) was used for quantification.

ChIP {#s09}
----

ChIP was performed according to the ChIP-IT kit protocol (Active Motif). Control IgG, RNA Pol II, and Ezh2 antibodies were from Active Motif. Control ChIP primers toward glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were from Active Motif. Primer sequences included forward (-7885) 5′-GCAACAGTTAGCATCATGGGC-3′, reverse (-7885) 5′-TGGGGTTGTAGGCTTTCCTG-3′, forward (-3389) 5′-CAGGCCATGGCTGTTTGATG-3′, reverse (-3389) 5′-CAGGTGCATGGGGTACAGAG-3′, forward (TSS) 5′-CGGAAAGGGGTTTGTTGCTGG-3′, reverse (TSS) 5′-GGGACGCCCCTGTCCTTTAC-3′.

Plasmids and pull-down assays {#s10}
-----------------------------

C2C12 cells were transfected with Myc-tagged Ddx3x ([NM_010028](NM_010028).3), Ddx5 ([NM_007840](NM_007840).3), DGCR8 ([NM_001190326](NM_001190326).1), Ezh2 ([NM_007971](NM_007971).2), Fus ([NM_139149](NM_139149).2), Fxr1 ([NM_008053](NM_008053).2), Stau1 ([NM_017453](NM_017453).3), Chronos 98-3259, Chronos 1467-3259, or pcDNA3.1^+^ using Lipofectamine 2000 (Thermo Fisher Scientific). Chronos 98-3259 and Chronos 1467-3259 were cloned into the pcDNA3.1^+^ vector. Cells were lysed in 10 mM Hepes, pH 7.9; 100 mM KCL; 2 mM MgCl~2~; 0.2 mM DTT; 200 U/ml RNase inhibitor; 1 mM ATP; 0.2 mM GTP; and 0.5% Triton X-100 and cleared by centrifugation at 10,000 *g* for 10 min at 4°C. Cleared lysates were diluted 1:3 with lysis buffer and incubated with EZview RED anti-c-Myc affinity gel (Sigma-Aldrich) at 4°C for 6 h with gentle rocking. Beads were subsequently washed five times with lysis buffer. C0mplete EDTA-free protease inhibitor (Roche) was present in all solutions from initial lysis to final wash. For protein analysis, beads were resuspended in 50 µl of 2× Laemmli buffer and stored at −20°C until size separation by SDS-PAGE and Western blot analysis. For RNA analysis, beads were resuspended in 1 ml of TRIzol (Thermo Fisher Scientific), and RNA was purified according to manufacturer's protocol. One-half of the RNA was reverse transcribed using random primers, and the other half was reserved as a negative control.

Nuclear extracts {#s11}
----------------

Nuclear extracts were prepared according to previously described methods ([@bib25]). In brief, the pellet of ∼6 × 10^6^ nonconfluent C2C12 cells were resuspended in ice-cold 0.1% NP-40 in PBS and centrifuged for 30 s at 10,000 *g* at 4°C. The pelleted nuclear fraction was resuspended in 1 ml RNA immunoprecipitation (RIP) buffer (150 mM KCl, 25 mM Tris pH 7.4, 0.5 mM DTT, 0.5% NP-40, and 1 mM PMSF) supplemented with C0mplete EDTA-free protease inhibitor and incubated on ice for 30 min with periodic vortexing. Nuclear debris was removed by centrifugation at 13,000 *g* for 10 min at 4°C.

RNA pull-down assay {#s12}
-------------------

RNA pull-down was performed according to previously described methods ([@bib35]). In brief, biotinylated RNAs were prepared using SP6 and T7 RNA polymerases (Roche) with biotin-16-uridine-5′-triphosphate (Bio-16-UTP; Invitrogen). RNAs were incubated at 90°C for 2 min and then placed on ice for 2 min. An equal volume of 2× RNA structure buffer (20 mM Tris HCL, pH 7.4; 0.2 M KCl; 20 mM MgCl~2~; 2 mM DTT; 0.8 U/µl RNase inhibitor) was added and incubated at RT for 20 min. Approximately 750--1000 µg of nuclear extract was mixed with ∼2.5 µg of RNA and incubated for 1 h at RT with rocking. 25 µl of washed streptavidin agarose beads (Invitrogen) was added and incubated for 1 h at RT with rocking. Beads were pelleted and washed five times with RIP buffer (150 mM KCl; 25 mM Tris, pH 74; 0.5 mM DTT; 0.5% NP-40; 1 mM PMSF) supplemented with protease inhibitor. Beads were resuspended in 50 µl of 2× Laemmli buffer and stored at −20°C until size separation by SDS-PAGE and Coomassie staining.

Motif analysis {#s13}
--------------

De novo motif analysis was performed in silico using MEME software at (<http://meme-suite.org>; The MEME Suite).

ELISA {#s14}
-----

Secreted mouse Bmp7 was quantified by sandwich ELISA according to manufacturer's protocol (LifeSpan BioSciences).

Western blot analysis {#s15}
---------------------

Cells were homogenized in 40 mM Tris, pH 7.4; 150 mM NaCl; 1% Triton X-100; and C0mplete EDTA-free protease inhibitor cocktail (Roche). Protein content was determined by the DC protein assay (Bio-Rad Laboratories) with known concentrations of BSA as standards. Protein concentrations were equalized by addition of an appropriate volume of lysis buffer. Primary antibody was visualized with HRP-conjugated goat anti--mouse and anti--rabbit secondary antibodies. Quantification was performed with ImageJ software (National Institutes of Health).

Protein synthesis analysis {#s16}
--------------------------

Puromycin (Millipore Sigma) was added to cell culture medium to a final concentration of 1 µM and incubated for 30 min as previously described ([@bib8]). At that dose, puromycin incorporation into neosynthesized proteins reflects the rate of mRNA translation in vitro ([@bib33]). Puromycin incorporation was detected by Western blot analysis.

Antibodies {#s17}
----------

Rabbit anti--phospho Smad1/5, rabbit anti--phospho Smad2, rabbit anti--Smad1/5, rabbit anti--Smad2, and rabbit anti--α/β tubulin antibodies were purchased from Cell Signaling Technology. Mouse anti--laminin antibodies were purchased from Sigma-Aldrich. Mouse anti--myosin (MF20) antibody was purchased from the Developmental Studies Hybridoma Bank at the University of Iowa. Rabbit anti--ubiquitin antibody was purchased from Abcam. Mouse Anti--GAPDH and mouse anti--puromycin antibodies were purchased from Millipore Sigma.

Immunohistochemistry and histologic analysis {#s18}
--------------------------------------------

Hind limb muscles were excised, fixed in 4% PFA, cryoprotected with 30% sucrose, and embedded in Tissue-Tek optimum cutting temperature formulation. Sections were cut transversely and subjected to immunostaining and nuclei counterstain with DAPI. C2C12 myoblasts were fixed in 4% PFA and subjected to immunostaining and nuclei counterstain with DAPI. Fixed tissues and cells were permeabilized with 0.05% Triton X-100 for 20 min and blocked with 5% normal donkey serum. Primary antibodies were visualized with cyanine Cy3 or Alexa-Flour 594 conjugated donkey anti--mouse antibodies from Jackson ImmunoResearch Laboratories. Coverslips were mounted with Aqua-Poly/Mount (Polysciences) or Vectashield (Vector Laboratories). All images were acquired at RT with a BZ-9000 fluorescence microscope (KEYENCE) using either a 10× PlanApo (NA 0.45) or a 20× PlanApo (NA 0.75) objective with the BZ-II Analyzer software (KEYENCE). Approximately 10--15 images were acquired from each transverse section. Myofiber cross-sectional areas were calculated using BZ-II Analyzer software or CellProfiler ([@bib15]).

Image processing {#s19}
----------------

Acquired images were minimally processed in Photoshop (Adobe). Contrast was enhanced with auto-contrast function on the whole-image file. Nuclei were false colored and overlaid onto the MF20 image with either the color or soft-light layer function.

Statistical methods {#s20}
-------------------

Data are presented as means ± SD unless indicated otherwise. Two-tailed, unpaired Student's *t* tests or two-way ANOVA were performed on experimental data from at least three individual experiments.

Online supplemental material {#s21}
----------------------------

Fig. S1 shows changes in the in vivo gene expression on d 7 after the injection of siChronos. Fig. S2 shows a schematic diagram of the Bmp7 locus and in silico analyses depicting the putative Chronos homology motif. Fig. S3 displays tandem mass spectrometry identification of RNA binding proteins precipitating with biotinylated Chronos and in vitro validation of the putative targets.
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